Alemtuzumab outcomes by age: Post hoc analysis from the randomized CARE-MS studies over 8 years

Ann D Bass,Rafael Arroyo,Aaron L Boster,Alexey N Boyko,Sara Eichau,Carolina Ionete,Volker Limmroth,Carlos Navas,Daniel Pelletier,Carlo Pozzilli, Jennifer Ravenscroft,Livia Sousa,Mar Tintoré,Bernard M J Uitdehaag,Darren P Baker,Nadia Daizadeh,Zia Choudhry,David Rog

Multiple Sclerosis and Related Disorders（2021）

引用 5|浏览4

暂无评分

摘要

•Across age groups, alemtuzumab efficacy was greater than SC IFNB-1a over 2 years.•Alemtuzumab maintained clinical and MRI efficacy over 8 years in all age groups.•Age-related increases in serious infections, malignancies, and deaths were observed.

查看译文

关键词

Alemtuzumab,Age,Efficacy,Long-term,Safety

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要